| 141.12 0.8 (0.57%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 177.75 | 1-year : | 207.61 |
| Resists | First : | 152.18 | Second : | 177.75 |
| Pivot price | 138.62  |
|||
| Supports | First : | 136.24 | Second : | 126.38 |
| MAs | MA(5) : | 139.49 |
MA(20) : | 138.94 |
| MA(100) : | 136.77 |
MA(250) : | 109.66 |
|
| MACD | MACD : | -1 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 52.5 |
D(3) : | 50.2 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 160.8 | Low : | 75.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PTGX ] has closed below upper band by 33.3%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 142.55 - 143.07 | 143.07 - 143.5 |
| Low: | 136.49 - 137.15 | 137.15 - 137.69 |
| Close: | 140.12 - 141.15 | 141.15 - 141.98 |
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Tue, 27 Oct 2026
BlackRock amends its Protagonist Therapeutics (PTGX) stake disclosure, naming an iShares ETF with over 5%. - Stock Titan
Tue, 27 Oct 2026
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026 - Yahoo Finance
Tue, 27 Oct 2026
10,448 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Robeco Institutional Asset Management B.V. - MarketBeat
Tue, 27 Oct 2026
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Average Target Price of $158.19 According to Analysts - MarketBeat
Mon, 26 Oct 2026
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo! Finance Canada
Sat, 24 Oct 2026
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 96 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 6.471e+007 (%) |
| Held by Institutions | 5.289e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.8199e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.02 |
| Profit Margin | 0 % |
| Operating Margin | 29.3 % |
| Return on Assets (ttm) | 74.3 % |
| Return on Equity (ttm) | 4.5 % |
| Qtrly Rev. Growth | 2.8199e+008 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 5.988e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 394.6 |
| Price to Book value | 137 |
| Price to Sales | 1.23576e+009 |
| Price to Cash Flow | 0 |
| Dividend | 9.35e+006 |
| Forward Dividend | 7.71e+006 |
| Dividend Yield | 6625570% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|